Page 27 - Molecular features of low-grade developmental brain tumours

GENERAL INTRODUCTION & OUTLINE OF THE THESIS
56. Merchant, T. E., Conklin, H. M., Wu, S., Lustig, R. H. & Xiong, X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27, 3691-3697, doi:10.1200/JCO.2008.21.2738 (2009).
57. Armstrong, G. T. et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 13, 223-234, doi:10.1093/neuonc/noq178 (2011).
58. Majores, M. et al. Tumor recurrence and malignant progression of gangliogliomas. Cancer 113, 3355-3363, doi:10.1002/cncr.23965 (2008).
59. Ray, W. Z. et al. Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol 94, 283-292, doi:10.1007/s11060-009-9849-9 (2009).
60. Banerjee, A. et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol 19, 1135-1144, doi:10.1093/neuonc/now282 (2017).
61. Franz, D. N. et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59, 490-498, doi:10.1002/ana.20784 (2006).
62. Slegers, R. J. & Blumcke, I. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta Neuropathol Commun 8, 27, doi:10.1186/s40478-020-00904-x (2020).
63. Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8, 30, doi:10.1186/s40478-020-00902-z (2020).
64. Martins, F. et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49, 293-298, doi:10.1016/j.oraloncology.2012.11.008 (2013).
65. Kondyli, M. et al. Trametinib for progressive pediatric low-grade gliomas. J Neurooncol 140, 435-444, doi:10.1007/s11060-018-2971-9 (2018).
66. Sievert, A. J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 110, 5957-5962, doi:10.1073/ pnas.1219232110 (2013).
67. Sapir, T. et al. Building Bridges Between the Clinic and the Laboratory: A Meeting Review - Brain Malformations: A Roadmap for Future Research. Front Cell Neurosci 13, 434, doi:10.3389/ fncel.2019.00434 (2019).
68. Curatolo, P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52, 281-289, doi:10.1016/j.pediatrneurol.2014.10.028 (2015).
69. Curatolo, P. et al. Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC. Eur J Paediatr Neurol 20, 203-211, doi:10.1016/j. ejpn.2015.12.005 (2016).
70. Curatolo, P., Moavero, R., van Scheppingen, J. & Aronica, E. mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert Rev Neurother 18, 185-201, doi:10.1080/14737175.2018.142856 2 (2018).
71. Northrup, H., Krueger, D. A. & International Tuberous Sclerosis Complex Consensus, G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49, 243-254, doi:10.1016/j. pediatrneurol.2013.08.001 (2013).
72. de Vries, P. J. et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis 13, 157, doi:10.1186/s13023-018-0901-8 (2018).
73. de Vries, P. J. et al. Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. Pediatr Neurol 52, 25-35, doi:10.1016/j.pediatrneurol.2014.10.004 (2015).
25
1